ECE2016 Eposter Presentations Diabetes therapy (44 abstracts)
Aim: To evaluate the effect of PPARG2 Pro12Ala, TNFα G(308)A and G(238)A, LIPC C(-514)T, ACE I/D, SLCO1B1 Val174Ala polymorphism on the response to statins therapy in patients with type 2 diabetes mellitus (T2DM).
Methods: We consecutively recruited patients with type 2 DM requiring lipid-lowering therapy according to current guidelines. Patients were started on either atorvastatin 10 or 20 mg. After 12 month of statin therapy, patients had fasting lipid profiles repeated. The alleles and genotypes were performed by PCR in real time with the TaqMan probes. Statistic analysis was evaluated using the MannWhitney/KruskalWallis and Wilcoxon tests, P<0.05.
Results: Ninety-seven patients were studied. There was no difference in total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels between the genotypes of studied genes in statin-untreated subjects. With statin therapy, PPARG2Pro/Pro patients had significantly TC and LDL-C lowering compared with PPARG2Pro/Ala and PPARG2 Ala/Ala patients (for TC: 20.74% vs. 4.6% and 5.61%; P=0.04, respectively; for LDL-C: 26.00% vs. 6.11% and 7.32%; P=0.029, respectively). There was no gender difference in baseline lipid parameters or response to statin therapy.
Conclusions: PPARG2 Pro12Ala polymorphism accounts for interindividual variability of response to statin therapy in patients with T2DM.